Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400218 | 1.00 | POLB (0.67) | POLBKMT2ATDP1MAPTLMNA | |
| SCHEMBL16824855 | 0.87 | POLB (0.73) | POLBKMT2ATDP1MAPTLMNA | |
| SCHEMBL3393724 | 0.85 | POLB (0.67) | POLBKMT2ATDP1MAPTLMNA | |
| SCHEMBL3187189 | 0.85 | HTR1A (0.64) | POLBKMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL2658444 | 0.83 | POLB (0.52) | POLBKMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL13833154 | 0.82 | KDM4E (0.60) | TDP1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1812473 | 0.82 | POLB (0.63) | POLBKMT2ATDP1MAPTLMNA | |
| SCHEMBL22471249 | 0.82 | POLB (0.63) | POLBKMT2ATDP1MAPTLMNA | |
| SCHEMBL3440117 | 0.82 | KMT2A (0.77) | POLBKMT2ATDP1MAPTSMN1; SMN2 | |
| SCHEMBL942109 | 0.81 | POLB (0.62) | POLBKMT2ATDP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318134-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2012-11-27 | — | — | US | disclosed |
| EP-1469890-B1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2011-08-10 | — | — | EP | disclosed |
| EP-2298362-A1 | Responsive paramagnetic MRI contrast agents | Bracco Imaging S.p.A (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7524483-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | MYT1, PRTN3, CECR2 | POLB 4103/4885KMT2A 2512/4885TDP1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.